BRD9 degradation disrupts ribosome biogenesis in multiple myeloma.

Keiji Kurata Mehmet Kemal Samur Priscilla Liow Kenneth Wen Leona Yamamoto Jiye Liu Eugenio Morelli Annamaria Gulla Yu-Tzu Tai Jun Qi Teru Hideshima Kenneth C Anderson

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Our study identifies and validates BRD9 as a novel therapeutic target in preclinical models of MM, which provides the framework for the clinical evaluation of BRD9 degraders to improve patient outcome.

Keyphrases

multiple myeloma
case report
genome wide
stem cells
mesenchymal stem cells
dna methylation